Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gene Rearrangement | 6 | 2019 | 1179 | 0.800 |
Why?
|
Gene Fusion | 3 | 2018 | 371 | 0.660 |
Why?
|
High-Throughput Nucleotide Sequencing | 13 | 2020 | 3585 | 0.520 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2020 | 704 | 0.470 |
Why?
|
Bile Duct Neoplasms | 2 | 2020 | 567 | 0.470 |
Why?
|
Codon | 2 | 2013 | 611 | 0.450 |
Why?
|
Nephrogenic Fibrosing Dermopathy | 1 | 2013 | 42 | 0.450 |
Why?
|
Genes, Neoplasm | 2 | 2014 | 376 | 0.450 |
Why?
|
Apocrine Glands | 1 | 2012 | 31 | 0.440 |
Why?
|
Eccrine Glands | 1 | 2012 | 45 | 0.430 |
Why?
|
PTEN Phosphohydrolase | 3 | 2015 | 1144 | 0.430 |
Why?
|
Chordoma | 2 | 2014 | 359 | 0.410 |
Why?
|
Proto-Oncogene Proteins c-met | 4 | 2018 | 578 | 0.400 |
Why?
|
Caveolin 1 | 1 | 2013 | 264 | 0.400 |
Why?
|
Cholangiocarcinoma | 1 | 2014 | 516 | 0.340 |
Why?
|
Thyroid Neoplasms | 4 | 2015 | 2274 | 0.340 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2013 | 644 | 0.340 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2017 | 1434 | 0.340 |
Why?
|
Germinal Center | 1 | 2011 | 377 | 0.330 |
Why?
|
Carcinoma | 3 | 2015 | 2374 | 0.300 |
Why?
|
Lung Neoplasms | 9 | 2018 | 13019 | 0.290 |
Why?
|
Pancreatic Cyst | 3 | 2016 | 368 | 0.290 |
Why?
|
Gene Dosage | 1 | 2011 | 1251 | 0.280 |
Why?
|
Chromosome Aberrations | 3 | 2013 | 1811 | 0.280 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 7 | 2018 | 5171 | 0.260 |
Why?
|
Sequence Analysis, DNA | 3 | 2018 | 4801 | 0.260 |
Why?
|
Mutation | 15 | 2020 | 29717 | 0.260 |
Why?
|
Lymphoma, B-Cell | 1 | 2011 | 930 | 0.250 |
Why?
|
In Situ Hybridization, Fluorescence | 6 | 2019 | 2638 | 0.250 |
Why?
|
Lactams, Macrocyclic | 2 | 2016 | 319 | 0.240 |
Why?
|
Protein Kinase Inhibitors | 8 | 2018 | 5522 | 0.210 |
Why?
|
Pyrazoles | 4 | 2016 | 1970 | 0.210 |
Why?
|
Cytodiagnosis | 2 | 2016 | 435 | 0.210 |
Why?
|
Glioblastoma | 2 | 2014 | 3456 | 0.210 |
Why?
|
Oncogene Proteins, Fusion | 3 | 2019 | 1581 | 0.210 |
Why?
|
Bile Ducts | 2 | 2020 | 284 | 0.200 |
Why?
|
Immunohistochemistry | 4 | 2013 | 11363 | 0.190 |
Why?
|
Proto-Oncogene Proteins c-myc | 2 | 2017 | 987 | 0.180 |
Why?
|
Receptor Protein-Tyrosine Kinases | 3 | 2016 | 1659 | 0.180 |
Why?
|
Pyridines | 3 | 2016 | 2818 | 0.170 |
Why?
|
Thrombocytosis | 1 | 2018 | 81 | 0.160 |
Why?
|
Cyst Fluid | 2 | 2016 | 76 | 0.160 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2018 | 5163 | 0.160 |
Why?
|
Granuloma, Plasma Cell | 1 | 2019 | 83 | 0.160 |
Why?
|
RNA-Binding Protein EWS | 1 | 2019 | 216 | 0.160 |
Why?
|
Oncogene Fusion | 2 | 2017 | 99 | 0.160 |
Why?
|
DNA-Binding Proteins | 2 | 2014 | 9639 | 0.160 |
Why?
|
Genes, p53 | 2 | 2020 | 755 | 0.150 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2015 | 15494 | 0.150 |
Why?
|
Paraffin Embedding | 2 | 2014 | 299 | 0.140 |
Why?
|
Carcinoma, Adenoid Cystic | 1 | 2019 | 252 | 0.140 |
Why?
|
Cystadenoma, Mucinous | 1 | 2016 | 59 | 0.140 |
Why?
|
Cystadenoma | 2 | 2015 | 84 | 0.140 |
Why?
|
Comparative Genomic Hybridization | 3 | 2012 | 496 | 0.130 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2017 | 1377 | 0.130 |
Why?
|
Transcription Factors | 2 | 2014 | 12164 | 0.130 |
Why?
|
Receptor, trkA | 1 | 2015 | 164 | 0.130 |
Why?
|
Neoplasm Proteins | 3 | 2016 | 3691 | 0.120 |
Why?
|
Adenocarcinoma | 3 | 2019 | 6347 | 0.120 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 783 | 0.120 |
Why?
|
Indazoles | 1 | 2015 | 287 | 0.120 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2019 | 602 | 0.120 |
Why?
|
Carcinoma, Papillary, Follicular | 1 | 2014 | 60 | 0.120 |
Why?
|
Tumor Suppressor Protein p53 | 4 | 2020 | 2948 | 0.120 |
Why?
|
High-Throughput Screening Assays | 2 | 2017 | 944 | 0.120 |
Why?
|
Biliary Tract Neoplasms | 1 | 2015 | 178 | 0.120 |
Why?
|
Genetic Testing | 2 | 2019 | 3439 | 0.120 |
Why?
|
Frameshift Mutation | 1 | 2015 | 399 | 0.120 |
Why?
|
Exons | 2 | 2016 | 2431 | 0.110 |
Why?
|
Hepatoblastoma | 1 | 2013 | 87 | 0.110 |
Why?
|
Mutagenesis, Insertional | 1 | 2015 | 655 | 0.110 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 199 | 0.110 |
Why?
|
Neoplasms, Adnexal and Skin Appendage | 1 | 2013 | 25 | 0.110 |
Why?
|
Rhabdomyosarcoma, Embryonal | 1 | 2013 | 102 | 0.110 |
Why?
|
Pancreatic Neoplasms | 3 | 2015 | 5249 | 0.110 |
Why?
|
Smad4 Protein | 3 | 2020 | 163 | 0.110 |
Why?
|
Fibromatosis, Aggressive | 1 | 2013 | 118 | 0.110 |
Why?
|
Myeloproliferative Disorders | 1 | 2018 | 603 | 0.110 |
Why?
|
Burkitt Lymphoma | 1 | 2014 | 328 | 0.110 |
Why?
|
Medical Informatics | 2 | 2016 | 742 | 0.100 |
Why?
|
Nevus, Blue | 1 | 2011 | 38 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2017 | 8425 | 0.100 |
Why?
|
Aged | 24 | 2019 | 162944 | 0.100 |
Why?
|
beta Catenin | 2 | 2014 | 1058 | 0.100 |
Why?
|
Liver Neoplasms | 3 | 2017 | 4249 | 0.100 |
Why?
|
Middle Aged | 27 | 2019 | 213127 | 0.100 |
Why?
|
Genomics | 3 | 2017 | 5692 | 0.100 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 5 | 2017 | 1683 | 0.100 |
Why?
|
Melanoma | 3 | 2017 | 5462 | 0.100 |
Why?
|
Wilms Tumor | 1 | 2013 | 368 | 0.090 |
Why?
|
Neutrophil Infiltration | 1 | 2013 | 390 | 0.090 |
Why?
|
Pathology, Clinical | 1 | 2014 | 368 | 0.090 |
Why?
|
Parietal Lobe | 1 | 2015 | 837 | 0.090 |
Why?
|
Humans | 49 | 2020 | 742088 | 0.090 |
Why?
|
Female | 36 | 2019 | 379592 | 0.090 |
Why?
|
Introns | 1 | 2013 | 991 | 0.090 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2014 | 589 | 0.090 |
Why?
|
Aged, 80 and over | 13 | 2019 | 57683 | 0.090 |
Why?
|
Benzamides | 1 | 2015 | 1378 | 0.090 |
Why?
|
NIH 3T3 Cells | 1 | 2011 | 677 | 0.090 |
Why?
|
Isocitrate Dehydrogenase | 1 | 2015 | 870 | 0.090 |
Why?
|
Gene Frequency | 2 | 2015 | 3587 | 0.090 |
Why?
|
Phosphoproteins | 1 | 2018 | 2440 | 0.090 |
Why?
|
Mutant Proteins | 1 | 2011 | 500 | 0.090 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2011 | 379 | 0.090 |
Why?
|
Hamartoma | 1 | 2011 | 234 | 0.090 |
Why?
|
Chromosome Deletion | 1 | 2014 | 1400 | 0.090 |
Why?
|
fms-Like Tyrosine Kinase 3 | 1 | 2013 | 491 | 0.090 |
Why?
|
Chromosomal Proteins, Non-Histone | 1 | 2014 | 730 | 0.080 |
Why?
|
Nevus, Pigmented | 1 | 2011 | 219 | 0.080 |
Why?
|
Drug Discovery | 1 | 2017 | 1057 | 0.080 |
Why?
|
Adult | 23 | 2019 | 213712 | 0.080 |
Why?
|
Mosaicism | 1 | 2011 | 440 | 0.080 |
Why?
|
Skin Neoplasms | 3 | 2013 | 5662 | 0.080 |
Why?
|
Male | 29 | 2019 | 349538 | 0.080 |
Why?
|
Gadolinium | 1 | 2013 | 951 | 0.080 |
Why?
|
Genes, p16 | 2 | 2020 | 157 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2016 | 9185 | 0.080 |
Why?
|
Microsatellite Instability | 1 | 2011 | 678 | 0.080 |
Why?
|
Polymerase Chain Reaction | 2 | 2014 | 6171 | 0.080 |
Why?
|
Carcinoma, Papillary | 1 | 2012 | 781 | 0.070 |
Why?
|
Terminology as Topic | 1 | 2014 | 1548 | 0.070 |
Why?
|
Biopsy | 5 | 2020 | 6756 | 0.070 |
Why?
|
Barrett Esophagus | 1 | 2011 | 494 | 0.070 |
Why?
|
Proto-Oncogene Proteins B-raf | 2 | 2016 | 2028 | 0.070 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3510 | 0.070 |
Why?
|
Fibrosis | 1 | 2013 | 2026 | 0.070 |
Why?
|
Computational Biology | 2 | 2017 | 3518 | 0.070 |
Why?
|
Lactams | 2 | 2016 | 155 | 0.070 |
Why?
|
Myelodysplastic Syndromes | 1 | 2015 | 1351 | 0.070 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2014 | 2455 | 0.060 |
Why?
|
Carcinoembryonic Antigen | 2 | 2016 | 347 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 2 | 2014 | 4553 | 0.060 |
Why?
|
Skin Diseases | 1 | 2013 | 1065 | 0.060 |
Why?
|
Young Adult | 10 | 2019 | 56350 | 0.060 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2015 | 1631 | 0.060 |
Why?
|
DNA Mutational Analysis | 4 | 2014 | 4187 | 0.060 |
Why?
|
Blotting, Western | 1 | 2011 | 5180 | 0.060 |
Why?
|
Neoplasms | 3 | 2019 | 21596 | 0.060 |
Why?
|
B-Lymphocytes | 1 | 2017 | 4664 | 0.060 |
Why?
|
Sulfones | 2 | 2016 | 437 | 0.060 |
Why?
|
Tumor Suppressor Proteins | 1 | 2013 | 2842 | 0.060 |
Why?
|
Crohn Disease | 1 | 2016 | 2301 | 0.060 |
Why?
|
Gene Amplification | 2 | 2018 | 1062 | 0.060 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2013 | 2915 | 0.050 |
Why?
|
Receptor, erbB-2 | 1 | 2012 | 2410 | 0.050 |
Why?
|
Brain Neoplasms | 2 | 2015 | 8829 | 0.050 |
Why?
|
Genetic Variation | 2 | 2017 | 6540 | 0.050 |
Why?
|
Aminopyridines | 2 | 2016 | 541 | 0.050 |
Why?
|
Software | 1 | 2016 | 4434 | 0.050 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2017 | 890 | 0.050 |
Why?
|
GTP Phosphohydrolases | 2 | 2016 | 508 | 0.050 |
Why?
|
Workflow | 2 | 2017 | 846 | 0.050 |
Why?
|
Fibroblasts | 1 | 2011 | 4143 | 0.050 |
Why?
|
Esophageal Neoplasms | 1 | 2011 | 1581 | 0.050 |
Why?
|
Contrast Media | 1 | 2013 | 5295 | 0.040 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2015 | 3497 | 0.040 |
Why?
|
Genetic Heterogeneity | 2 | 2014 | 732 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2017 | 3557 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12242 | 0.040 |
Why?
|
Ki-67 Antigen | 2 | 2011 | 644 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 11472 | 0.040 |
Why?
|
Thyroidectomy | 2 | 2015 | 877 | 0.040 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5304 | 0.040 |
Why?
|
Calmodulin-Binding Proteins | 1 | 2019 | 249 | 0.040 |
Why?
|
Cytogenetic Analysis | 1 | 2018 | 295 | 0.040 |
Why?
|
Vision Disorders | 2 | 2015 | 1057 | 0.040 |
Why?
|
Ribosomal Protein S6 Kinases | 1 | 2017 | 205 | 0.040 |
Why?
|
Disease Progression | 3 | 2019 | 13256 | 0.040 |
Why?
|
DNA Copy Number Variations | 2 | 2019 | 1940 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-raf | 1 | 2017 | 203 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-kit | 2 | 2011 | 774 | 0.040 |
Why?
|
Genome, Human | 3 | 2015 | 4420 | 0.040 |
Why?
|
Receptors, Steroid | 1 | 2017 | 155 | 0.040 |
Why?
|
Neoplasm Staging | 3 | 2019 | 11001 | 0.040 |
Why?
|
K562 Cells | 1 | 2018 | 632 | 0.040 |
Why?
|
DNA, Neoplasm | 2 | 2012 | 1758 | 0.040 |
Why?
|
Neuregulin-1 | 1 | 2017 | 142 | 0.030 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2018 | 433 | 0.030 |
Why?
|
Colorectal Neoplasms | 1 | 2016 | 6754 | 0.030 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2017 | 215 | 0.030 |
Why?
|
Phenotype | 1 | 2013 | 16331 | 0.030 |
Why?
|
Pyrimidinones | 1 | 2017 | 370 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2013 | 21719 | 0.030 |
Why?
|
Paraffin | 1 | 2014 | 35 | 0.030 |
Why?
|
Biliary Tract | 1 | 2015 | 134 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6534 | 0.030 |
Why?
|
Chromogranins | 1 | 2015 | 163 | 0.030 |
Why?
|
False Negative Reactions | 1 | 2015 | 587 | 0.030 |
Why?
|
Preoperative Period | 1 | 2016 | 546 | 0.030 |
Why?
|
Aphasia | 1 | 2015 | 179 | 0.030 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2015 | 319 | 0.030 |
Why?
|
Quality Control | 1 | 2017 | 841 | 0.030 |
Why?
|
Pyrimidines | 2 | 2016 | 2933 | 0.030 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 290 | 0.030 |
Why?
|
Liver Failure | 1 | 2015 | 240 | 0.030 |
Why?
|
Signal Transduction | 1 | 2017 | 23387 | 0.030 |
Why?
|
Microsatellite Repeats | 1 | 2016 | 800 | 0.030 |
Why?
|
Estrogen Receptor alpha | 1 | 2017 | 577 | 0.030 |
Why?
|
Tissue Fixation | 1 | 2014 | 241 | 0.030 |
Why?
|
RNA Editing | 1 | 2014 | 148 | 0.030 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 1 | 2015 | 202 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2020 | 14720 | 0.030 |
Why?
|
Oligodeoxyribonucleotides | 1 | 2014 | 708 | 0.030 |
Why?
|
Keratin-19 | 1 | 2013 | 33 | 0.030 |
Why?
|
Keratin-17 | 1 | 2013 | 26 | 0.030 |
Why?
|
Formaldehyde | 1 | 2014 | 353 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2014 | 6891 | 0.030 |
Why?
|
Pyridones | 1 | 2017 | 712 | 0.030 |
Why?
|
Cholangiopancreatography, Endoscopic Retrograde | 1 | 2015 | 504 | 0.030 |
Why?
|
Fluorescent Antibody Technique | 1 | 2017 | 2505 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2017 | 1875 | 0.030 |
Why?
|
Vincristine | 1 | 2014 | 1036 | 0.030 |
Why?
|
Prognosis | 3 | 2019 | 29010 | 0.030 |
Why?
|
Base Sequence | 2 | 2015 | 12797 | 0.030 |
Why?
|
Survival Analysis | 2 | 2016 | 10248 | 0.030 |
Why?
|
Adolescent | 6 | 2019 | 85649 | 0.030 |
Why?
|
Child, Preschool | 4 | 2019 | 40955 | 0.030 |
Why?
|
Mice, SCID | 1 | 2017 | 2715 | 0.030 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 694 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2013 | 17400 | 0.020 |
Why?
|
Molecular Structure | 1 | 2015 | 1907 | 0.020 |
Why?
|
Pathology, Molecular | 1 | 2014 | 325 | 0.020 |
Why?
|
Craniotomy | 1 | 2015 | 729 | 0.020 |
Why?
|
Immunophenotyping | 1 | 2016 | 1866 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2020 | 2968 | 0.020 |
Why?
|
Brain Edema | 1 | 2015 | 617 | 0.020 |
Why?
|
Mice, Nude | 1 | 2017 | 3689 | 0.020 |
Why?
|
GTP-Binding Protein alpha Subunits | 1 | 2011 | 100 | 0.020 |
Why?
|
GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2011 | 140 | 0.020 |
Why?
|
Quinazolines | 1 | 2017 | 1355 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2017 | 16665 | 0.020 |
Why?
|
Reimbursement Mechanisms | 1 | 2016 | 670 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2017 | 20774 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1567 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2019 | 19862 | 0.020 |
Why?
|
Mice | 2 | 2017 | 81045 | 0.020 |
Why?
|
Sequence Deletion | 1 | 2013 | 1526 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2017 | 2502 | 0.020 |
Why?
|
Pancreas | 1 | 2015 | 1684 | 0.020 |
Why?
|
Cyclophosphamide | 1 | 2014 | 2236 | 0.020 |
Why?
|
Indoles | 1 | 2017 | 1834 | 0.020 |
Why?
|
Chromatin | 1 | 2020 | 2917 | 0.020 |
Why?
|
Oncogenes | 1 | 2014 | 1263 | 0.020 |
Why?
|
Genes, ras | 1 | 2011 | 691 | 0.020 |
Why?
|
Membrane Proteins | 2 | 2016 | 7873 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2215 | 0.020 |
Why?
|
Melanocytes | 1 | 2011 | 515 | 0.020 |
Why?
|
Child | 4 | 2019 | 77478 | 0.020 |
Why?
|
Pancreatectomy | 1 | 2012 | 802 | 0.020 |
Why?
|
Research | 1 | 2016 | 1999 | 0.020 |
Why?
|
Animals | 3 | 2017 | 168561 | 0.020 |
Why?
|
Sulfonamides | 1 | 2017 | 1932 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2017 | 5062 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2011 | 1950 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2014 | 1780 | 0.020 |
Why?
|
Binding Sites | 1 | 2015 | 6115 | 0.020 |
Why?
|
Administration, Oral | 1 | 2014 | 3913 | 0.020 |
Why?
|
Diagnosis, Differential | 2 | 2013 | 12958 | 0.020 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39004 | 0.020 |
Why?
|
Genetic Association Studies | 1 | 2016 | 2699 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2017 | 4839 | 0.020 |
Why?
|
Quality Assurance, Health Care | 1 | 2017 | 2211 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5872 | 0.020 |
Why?
|
Risk Factors | 1 | 2013 | 72145 | 0.020 |
Why?
|
ras Proteins | 1 | 2011 | 1060 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2011 | 1038 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2633 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2012 | 2906 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2016 | 2723 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2014 | 2938 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2016 | 5867 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2020 | 13921 | 0.020 |
Why?
|
Alleles | 1 | 2015 | 6931 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2016 | 3527 | 0.010 |
Why?
|
Prospective Studies | 2 | 2019 | 53187 | 0.010 |
Why?
|
Cohort Studies | 2 | 2015 | 40450 | 0.010 |
Why?
|
DNA Methylation | 1 | 2016 | 4282 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2017 | 14554 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 7901 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2016 | 10472 | 0.010 |
Why?
|
Cell Line | 1 | 2014 | 15994 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2019 | 77098 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2018 | 62966 | 0.010 |
Why?
|
Skin | 1 | 2013 | 4353 | 0.010 |
Why?
|
Smoking | 1 | 2016 | 8969 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 12946 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9410 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15056 | 0.010 |
Why?
|
Time Factors | 1 | 2018 | 40054 | 0.010 |
Why?
|
Prevalence | 1 | 2013 | 15194 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 12071 | 0.010 |
Why?
|
Risk Assessment | 1 | 2012 | 23320 | 0.010 |
Why?
|
Infant | 1 | 2011 | 35070 | 0.010 |
Why?
|